- Home
- BHF vs IBRX Comparison
BHF vs IBRX Comparison
Compare BHF & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHF
- IBRX
- Stock Information
- Founded
- BHF 2016
- IBRX 2014
- Country
- BHF United States
- IBRX United States
- Employees
- BHF N/A
- IBRX N/A
- Industry
- BHF Life Insurance
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BHF Finance
- IBRX Health Care
- Exchange
- BHF Nasdaq
- IBRX Nasdaq
- Market Cap
- BHF 2.8B
- IBRX 2.4B
- IPO Year
- BHF N/A
- IBRX N/A
- Fundamental
- Price
- BHF $59.81
- IBRX $2.66
- Analyst Decision
- BHF Hold
- IBRX Strong Buy
- Analyst Count
- BHF 10
- IBRX 5
- Target Price
- BHF $57.90
- IBRX $11.40
- AVG Volume (30 Days)
- BHF 846.7K
- IBRX 11.3M
- Earning Date
- BHF 05-08-2025
- IBRX 05-12-2025
- Dividend Yield
- BHF N/A
- IBRX N/A
- EPS Growth
- BHF N/A
- IBRX N/A
- EPS
- BHF 8.45
- IBRX N/A
- Revenue
- BHF $8,610,000,000.00
- IBRX $31,222,000.00
- Revenue This Year
- BHF $42.62
- IBRX $579.01
- Revenue Next Year
- BHF $2.05
- IBRX $173.61
- P/E Ratio
- BHF $7.08
- IBRX N/A
- Revenue Growth
- BHF 165.09
- IBRX 10238.41
- 52 Week Low
- BHF $40.00
- IBRX $1.83
- 52 Week High
- BHF $64.12
- IBRX $7.63
- Technical
- Relative Strength Index (RSI)
- BHF 55.86
- IBRX 53.05
- Support Level
- BHF $58.18
- IBRX $2.43
- Resistance Level
- BHF $60.94
- IBRX $2.79
- Average True Range (ATR)
- BHF 1.81
- IBRX 0.23
- MACD
- BHF -0.19
- IBRX 0.02
- Stochastic Oscillator
- BHF 48.37
- IBRX 53.80
About BHF Brighthouse Financial Inc.
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.